Skip to content
RushPR News – Lifestyle
Author:
Galimedix Therapeutics, Inc.
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies
October 1, 2026
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
September 11, 2026
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
March 12, 2026